The Study
Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study
This study found that certain proteins in the blood were more common in older people who later had trouble remembering things. But it didn’t change those proteins—it just noticed they were linked. So we can’t say the proteins cause memory problems, just that they show up together.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists checked blood levels of certain proteins in older adults who were at risk of falling or moving slowly, to see if those proteins could predict memory problems.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 583 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — these proteins may help identify older adults most likely to develop memory issues, even before symptoms appear.
- 2People with the highest levels of MPO had almost twice the chance of developing memory problems over 2 years.
- 3Same with MMP7 — highest levels meant more than double the risk.
- 4But high MMP1 was linked to lower risk of memory problems at the start.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of Nutrition, Health & Aging
Year
2025
Authors
M. M. Mielke, R. Fielding, Elizabeth J Atkinson, Zaira Aversa, M. Schafer, Steven R. Cummings, Marco Pahor, Christiaan Leeuwenburgh, N. LeBrasseur
Related Content
Claims (6)
Older adults with mobility limitations who have higher initial levels of five specific blood proteins are more likely to experience faster loss of physical function and a greater chance of becoming severely mobility-limited within two years, regardless of any treatment or changes in body weight.
Older adults aged 70–80 at high risk of mobility disability with higher levels of MMP1 in their blood have lower rates of mild cognitive impairment at the time of measurement compared to those with lower levels.
Older adults aged 70–80 at high risk of mobility disability who have higher levels of MMP7 in their blood are more likely to develop mild cognitive impairment or dementia within two years than those with lower levels.
Higher levels of myeloperoxidase in the blood are linked to a greater likelihood of mild cognitive impairment in older adults aged 70–80 who are at high risk of mobility disability, both at a single point in time and over time.
Older adults aged 70–80 at high risk of mobility disability with higher levels of myeloperoxidase in their blood have a higher likelihood of developing mild cognitive impairment or dementia over two years compared to those with lower levels.
In older adults aged 70–80 at high risk of mobility disability, elevated levels of myeloperoxidase and MMP7 in blood are consistently linked to the development of mild cognitive impairment or dementia over 24 months, while other biomarkers including MMP1, GDF15, and IL-6 are not linked to this outcome.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.